Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06548360 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

Study acronym: TRuE-VIP1
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 9 months later Aug 10, 2026 → Jun 5, 2028
See other at-risk trials from Incyte

Record History

  1. Primary completion pushed from Aug 10, 2026 to Jun 5, 2028 Completion pushed from Mar 13, 2027 to Dec 20, 2028v50 Show 1 more changeShow less
    • Completion pushed from Mar 13, 2027 to Dec 20, 2028
  2. Trial sites reduced: 101 → 98 locationsv49
  3. Study sites: 99 to 101 Eligibility criteria shortened, about 4 wordsv48 Show 1 more changeShow less
    • Eligibility criteria shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 102 to 99v47
  5. Study sites: 99 to 102v46
Show 44 earlier versionsHide 44 earlier versions
  1. Site details revised at 6 of 99 sitesv45
  2. Study sites: 97 to 99v44
  3. Study sites: 99 to 97v43
  4. Study sites: 97 to 99v42
  5. Study sites: 98 to 97v41
  6. Study sites: 95 to 98v40
  7. Study sites: 96 to 95v39
  8. Site details revised at 3 of 96 sitesv38
  9. Study sites: 94 to 96v37
  10. Study sites revised (94)v36 See this version in full on ClinicalTrials.gov ↗
  11. Study sites: 93 to 94v35
  12. Study sites: 92 to 93v34
  13. Study sites: 91 to 92v33
  14. Study sites: 92 to 91v32
  15. Study sites: 91 to 92v31
  16. Study sites: 92 to 91v30
  17. Study sites: 91 to 92v29
  18. Study sites: 92 to 91v28
  19. Study sites: 91 to 92v27
  20. Study sites: 92 to 91v26
  21. Study sites: 91 to 92v25
  22. Site details revised at 2 of 91 sitesv24
  23. Study sites: 92 to 91v23
  24. Study sites: 91 to 92v22
  25. Study sites: 92 to 91v21
  26. Study sites: 91 to 92v20
  27. Study sites revised (91)v19 See this version in full on ClinicalTrials.gov ↗
  28. Study sites: 89 to 91v18
  29. Study sites: 87 to 89v17
  30. Study sites revised (87)v16 See this version in full on ClinicalTrials.gov ↗
  31. Study sites: 86 to 87v15
  32. Study sites: 85 to 86v14
  33. Study sites: 84 to 85v13
  34. Study sites: 83 to 84v12
  35. Study sites: 79 to 83v11
  36. Study sites revised (79)v10 See this version in full on ClinicalTrials.gov ↗
  37. Study sites: 76 to 79v9
  38. Study sites: 77 to 76v8
  39. Study sites: 74 to 77v7
  40. Study sites: 73 to 74v6
  41. Study sites: 62 to 73 Start date changed from estimate of Dec 16, 2024 to Jan 24, 2025v5 Show 1 more changeShow less
    • Start date changed from estimate of Dec 16, 2024 to Jan 24, 2025
  42. Study sites revised (62)v4 See this version in full on ClinicalTrials.gov ↗
  43. Study sites: 61 to 62v3
  44. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 61 · Start date: Nov 18, 2024 to Dec 16, 2024v2 Show 2 more changesShow less
    • Study sites: 0 to 61
    • Start date: Nov 18, 2024 to Dec 16, 2024
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Incyte
94 trials monitored
See 9 trials at risk
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
Trial Details
NCT Number NCT06548360
Lead Sponsor Incyte Corporation
Conditions NonSegmental Vitiligo
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov